Compare · ORKA vs TKNO
ORKA vs TKNO
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Alpha Teknova Inc. (TKNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and TKNO operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $4.89B, about 12.0x TKNO ($408.0M).
- ORKA has been more active in the news (3 items in the past 4 weeks vs 1 for TKNO).
- ORKA has more recent analyst coverage (11 ratings vs 10 for TKNO).
- Company
- Oruka Therapeutics Inc.
- Alpha Teknova Inc.
- Price
- -
- -
- Market cap
- $4.89B
- $408.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 1
- Recent ratings
- 11
- 10
Latest ORKA
- SEC Form 4 filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
- Senior Vice President, Finance Agarwal Arjun sold $51,035 worth of shares (533 units at $95.75) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 14,219 units (SEC Form 4)
- General Counsel Quinlan Paul T exercised 10,000 shares at a strike of $7.80 and sold $936,417 worth of shares (10,000 units at $93.64) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)
- Senior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax
- General Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax
Latest TKNO
- Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System
- Jefferies initiated coverage on Alpha Teknova with a new price target
- Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling
- Alpha Teknova upgraded by BTIG Research with a new price target
- SEC Form 10-Q filed by Alpha Teknova Inc.
- Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Teknova Reports Second Quarter 2026 Financial Results
- Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes
- Roth Capital initiated coverage on Alpha Teknova with a new price target
- Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026